Neurocrine +14% after FDA approves tardive dyskinesia medication

|About: Neurocrine Biosciences, Inc. (NBIX)|By:, SA News Editor

Neurocrine Biosciences (NASDAQ:NBIX) +14.3% AH after saying it received FDA approval of its Ingrezza capsules as the first and only approved treatment for adults with tardive dyskinesia neurological disorder.

NBIX says the drug will be in the distribution channel next week and will be available through a select pharmacy network.